Lei Cheng

Dr. Lei Cheng

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
XCXingdong Chen
Xingdong Chen
JGJeffrey Gole
Jeffrey Gole
AGAthurva Gore
Athurva Gore
QHQiye He
Qiye He
MLMing Lu
Ming Lu
LJLi Jin
Li Jin
Early detection has the potential to reduce cancer mortality, but an effective screening test must demonstrate asymptomatic cancer detection years before conventional diagnosis in a longitudinal study. In the Taizhou Longitudinal Study (TZL), 123,115 healthy subjects provided plasma samples for long-term storage and were then monitored for cancer occurrence. Here we report the preliminary results of PanSeer, a noninvasive blood test based on circulating tumor DNA methylation, on TZL plasma samples from 605 asymptomatic individuals, 191 of whom were later diagnosed with stomach, esophageal, colorectal, lung or liver cancer within four years of blood draw. We also assay plasma samples from an additional 223 cancer patients, plus 200 primary tumor and normal tissues. We show that PanSeer detects five common types of cancer in 88% (95% CI: 80–93%) of post-diagnosis patients with a specificity of 96% (95% CI: 93–98%), We also demonstrate that PanSeer detects cancer in 95% (95% CI: 89–98%) of asymptomatic individuals who were later diagnosed, though future longitudinal studies are required to confirm this result. These results demonstrate that cancer can be non-invasively detected up to four years before current standard of care.

4 May 2012 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
LCLei Cheng
Lei Cheng
PWPing Wang
Ping Wang
SYSheng Yang
Sheng Yang
YYYanqing Yang
Yanqing Yang
QZQing Zhang
Qing Zhang
QZQinghua Zhang
Qinghua Zhang
Background: To elucidate gene expression associated with copy number changes, we performed a genome-wide copy number and expression microarray analysis of 25 pairs of gastric tissues. Methods: We applied laser capture microdissection (LCM) to obtain samples for microarray experiments and profiled DNA copy number and gene expression using 244K CGH Microarray and Human Exon 1.0 ST Microarray. Results: Obviously, gain at 8q was detected at the highest frequency (70%) and 20q at the second (63%). We also identified molecular genetic divergences for different TNM-stages or histological subtypes of gastric cancers. Interestingly, the C20orf11 amplification and gain at 20q13.33 almost separated moderately differentiated (MD) gastric cancers from poorly differentiated (PD) type. A set of 163 genes showing the correlations between gene copy number and expression was selected and the identified genes were able to discriminate matched adjacent noncancerous samples from gastric cancer samples in an unsupervised two-way hierarchical clustering. Quantitative RT-PCR analysis for 4 genes (C20orf11, XPO5, PUF60, and PLOD3) of the 163 genes validated the microarray results. Notably, some candidate genes (MCM4 and YWHAZ) and its adjacent genes such as PRKDC, UBE2V2, ANKRD46, ZNF706, and GRHL2, were concordantly deregulated by genomic aberrations. Conclusions: Taken together, our results reveal diverse chromosomal region alterations for different TNM-stages or histological subtypes of gastric cancers, which is helpful in researching clinicopathological classification, and highlight several interesting genes as potential biomarkers for gastric cancer.

1 December 2012 in Cancer Letters
Verified
Journal Article
Closed access
LCLei Cheng
Lei Cheng
SYSheng Yang
Sheng Yang
YYYanqing Yang
Yanqing Yang
WZWen Zhang
Wen Zhang
HXHuasheng Xiao
Huasheng Xiao
QZQinghua Zhang
Qinghua Zhang

1 October 2013 in Genomics
Verified
Journal Article
Closed access
LCLei Cheng
Lei Cheng
QZQing Zhang
Qing Zhang
SYSheng Yang
Sheng Yang
YYYanqing Yang
Yanqing Yang
WZWen Zhang
Wen Zhang
QZQinghua Zhang
Qinghua Zhang

22 May 2018 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
LYLin Yang
Lin Yang
ZYZhou Yang
Zhou Yang
LCLei Cheng
Lei Cheng
JCJuan Cheng
Juan Cheng
LCLi Cheng
Li Cheng
QZQinghua Zhang
Qinghua Zhang

15 May 2023 in Cancer Medicine
Verified
Journal Article
Open access
LCLei Cheng
Lei Cheng
GGGuanghui Gao
Guanghui Gao
CZChao Zhao
Chao Zhao
HWHaowei Wang
Haowei Wang
CYChao Yao
Chao Yao
CZCaicun Zhou
Caicun Zhou
Objective: Immune checkpoint inhibitors (ICIs) or combined with chemotherapy exhibit substantial efficacy for the treatment of advanced non‐small cell lung cancer (NSCLC). However, reliable biomarkers that can monitor response to first‐line ICIs ± chemotherapy remain unclear.Methods: A total of 16 tumor tissues and 46 matched peripheral blood samples at baseline and during treatment were retrospectively collected from 19 locally advanced or metastatic NSCLC patients. The circulating tumor DNA (ctDNA) burden by tumor‐informed assay was detected to monitor and predict the therapeutic response and survival of NSCLC patients treated with first‐line ICIs or plus chemotherapy.Results: We found that ctDNA was only positively detected in one patient by tumor‐agnostic assay with a mean variant allele fraction (VAF) of 6.40%, whereas it was positively detected in three patients by tumor‐informed assay with a mean VAF of 8.83%, 0.154%, and 0.176%, respectively. Tumor‐informed assays could sensitively detect ctDNA in 93.75% (15/16) of patients. Trends in the level of ctDNA from baseline to first evaluation was consistent with the radiographic changes. There was a greater decrease in ctDNA after treatment compared with baseline in patients with partial response compared to patients with stable disease/progressive disease. Patients with over a 50% reduction in ctDNA had a significant progression‐free survival and overall survival benefit.Conclusion: The tumor‐informed assay was favorable for ctDNA detection, and early dynamic changes in plasma ctDNA may be a valuable biomarker for monitoring the efficacy and predicting the outcome in advanced NSCLC patients treated with first‐line ICIs ± chemotherapy.